Eucrates Biomedical Acquisition Corp.

Eucrates Biomedical Acquisition Corp. (Nasdaq: EUCR) is a blank check company formed to pursue a business combination in the biomedical and life sciences sector. The company completed its initial public offering in 2021 and filed a Form 10-Q with the Securities and Exchange Commission on August 16, 2021, accession number 0001104659-21-106198, documenting its financial position during the active search phase. The quarterly filing reflects the company's standing as a healthcare-focused SPAC working to identify a qualifying acquisition target within the broader biomedical industry. For full filing history, sponsor details, deal timeline, and analytics on EUCR and hundreds of other SPACs, sign up for complete data on SpacDesk.